Menu
Washingtoner
  • Home
  • Business
  • Construction
  • Technology
  • Arts
  • Health
  • Property
  • Software
  • Marketing
Washingtoner

CCHR Urges FDA Overhaul to End Psychiatric Drug and Device Harms
Washingtoner/10275453

Trending...
  • Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
  • Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
  • Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
CCHR Urges FDA Overhaul
The Mental Health Watchdog calls for reforms to protect public safety, citing decades of antidepressant, electroshock, and psychedelic drug risks.

LOS ANGELES - Washingtoner -- The Citizens Commission on Human Rights International is calling for an overhaul of mental health agencies to eliminate potential conflicts of interest that may be putting patients at risk. The 55-year mental health industry watchdog said oversight should focus on the Food and Drug Administration (FDA), the agency tasked with ensuring the safety, efficacy, and security of drugs, biological products, and medical devices.

This reform is particularly urgent, CCHR says, given the FDA's ongoing failure to address critical issues, including the fact that it has yet to ban a skin electroshock device used as painful behavior modification on students with autism and intellectual and mental handicaps. In March 2024, the FDA announced that an electrical stimulation device (ESD) for behavior modification presents an "unreasonable and substantial risk of illness or injury." It called for submissions but has yet to issue a final order prohibiting it.[1] Meanwhile, children and adults continue to be subjected to it.

This is despite, as early as 2012, Juan Mendez, the United Nations Special Rapporteur on Torture said using this aversion therapy device constituted torture. According to a human rights lawyer, "The passage of electricity through anybody's body is clearly associated with pain and suffering."[2] Health agencies and psychiatric associations allow electroconvulsive therapy (ECT) to continue to be given to children and adolescents, as well as to any individual without their consent—a practice the UN also considers coercion and torture. No clinical trials have proven the safety and efficacy of ECT.[3]

CCHR has long advocated for the FDA to recognize the dangers of electroshock and to protect the public from the mass reliance upon antidepressants and other psychotropic drugs that pose significant health risks. The group says critical warnings about the link between antidepressants and increased suicidality and violent behavior have been ignored.

More on Washingtoner
  • Spokane River Flows Meet Level 2 Drought Response
  • California Family Launches Billboard to Reach "Pardon Czar" Alice Marie Johnson
  • Rent Like A Champion Acquires CollegeWeekends
  • Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
  • Seligson Law Launches New Website to Support Cannabis Businesses in California and New York

CCHR is concerned about how psychedelic drug applications are advancing through the agency, which, if approved, may increase acts of violence in the community. In June 2024, the FDA granted "Breakthrough Therapy Designation" to the hallucinogen psilocybin as an adjunct to treat "major depressive disorder." The designation is usually reserved for drugs that substantially improve over existing therapies in treating severe or life-threatening conditions.[4] Earlier, the FDA published guidelines for researchers to meet challenges in designing psychedelic drug development programs. "Psychedelic drugs may produce psychoactive effects such as mood and cognitive changes, as well as hallucinations. As a result, there is the potential for abuse of these drugs, which is a drug safety issue," according to the FDA.[5]

The U.S. is already plagued by acts of senseless violence, including school and community shootings, committed by people taking or withdrawing from psychiatric drugs. Psychedelics, if approved, could add to this. For years, the links between antidepressants and suicidality or violent behavior were suppressed, as documented by CCHR and medical experts.

The breakthrough SSRI antidepressant, fluoxetine, was approved in December 1987. By 1991, sales of the drug had reached nearly $1 billion and 3.5 million patients had taken it. The Los Angeles Times reported that antidepressants had been dogged by controversy over it being linked to suicide, homicide and other violence. The campaign exposing its risks was spearheaded by CCHR, a watchdog group that was established by the Church of Scientology in 1969 to investigate and expose psychiatric violations of human rights, including the failure to properly inform about treatment risks and harm. Sales "would be substantially higher" were it not for this campaign, said Steven Gerber, a securities analyst with Bateman Eichler in Los Angeles. According to the LA Times, "The campaign, which included involvement in dozens of criminal and civil suits, has nonetheless been surprisingly successful, alarming both potential patients and their doctors and contributing to the halt in growth of the drug's sales in [1991]."[6]

CCHR's Freedom of Information Act requests, review of court documents and media investigation findings reveal a scandalous history of cover-up of adverse drug effects. According to documents obtained in litigation, as early as 1984, German regulators had expressed concerns about fluoxetine and an increased risk of suicidality—three years before it was approved for the U.S. market. In 1990, FDA officer, Dr. David Graham reviewed the clinical trials and warned of large-scale under-reporting of suicidality.[7] An initially undisclosed memo from an antidepressant manufacturer admitted a rate of suicide to be 5.6 times higher than for the older tricyclic antidepressant, imipramine.[8] Adverse effects within two years of the drug being approved had reached nearly double those for an older antidepressant that had been on the market for 20 years.[9]

More on Washingtoner
  • South Tacoma Groundwater Protection District Code Update Public Hearing on August 12
  • databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
  • AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
  • WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
  • CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond

FDA officials continued to find suicide and violence to be of concern, such as Dr. Andrew Mosholder, an FDA Safety Reviewer, who provided his findings to the FDA, but these were not released publicly.[10] The brazen refusal to publicly acknowledge the risks came to a head in 2004 when the U.S. House Energy and Commerce Subcommittee on Oversight and Investigations began an investigation.[11] Shortly after, the FDA added a black box warning of suicidality to SSRI antidepressant packaging for those 18 and younger, extending this later to age 24.

CCHR says that a comprehensive review of the FDA's review, approval and monitoring process for psychotropic drugs and psychiatric devices is vital to safeguarding public health and ensuring the protection of patients.

Sources:

[1] www.cchrint.org/2024/03/29/fda-again-pursues-ban-on-behavioral-electroshock-device/; www.thesunchronicle.com/news/local_news/fda-moves-again-to-ban-controversial-shock-therapy-devices-used-by-rotenberg-center/article_5b3792d4-3dd0-5745-a92b-332edf69b33f.html
[2] web.archive.org/web/20120623234442/http://www.myfoxboston.com/story/18840703/2012/06/20/un-investigating-judge-rotenberg-centers-use-of-shocks
[3] www.wisnerbaum.com/defective-medical-device-injuries/ect/
[4] med.uth.edu/psychiatry/2024/06/03/fda-grants-breakthrough-therapy-designation-to-cyb003-a-deuterated-psilocybin-analog-being-investigated-as-an-adjunctive-treatment-for-major-depressive-disorder-mdd/
[5] www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
[6] www.latimes.com/archives/la-xpm-1992-01-08-fi-1610-story.html
[7] Joseph Glenmullen, M.D., Prozac Backlash, (New York, NY: Simon & Schuster, 2000) p. 162; www.wisnerbaum.com/our-successes/advocacy-campaigns/antidepressant-trials-adult-suicidality-data/
[8] Dr. Richard DeGrandpre, "Anti-depressants may be hazardous to your health," Hartford Advocate, 20 Aug 2002
[9] Craig McLaughlin, "The Perils of Prozac," San Francisco Bay Guardian, 16 May 1996
[10] www.cchrint.org/cchrs-exposure-of-antidepressant-risks-false-marketing-of-the-chemical-imbalance-theory/#_edn124
[11] "Barton, Greenwood Seek Info From FDA On Antidepressants," Rep. Barton's website, 24 Mar. 2004

Contact
Citizens Commission on Human Rights International
***@cchr.org


Source: Citizens Commission on Human Rights
Filed Under: Government

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • "The Pornified Generation": Dr. Chris Samuels Exposes the Toxic Alliance Between Bro Culture and Pornography That's Rewiring a Generation
  • Spokane: Suspect in custody after deliberately set fire causes damage to building housing the Downtown Police Precinct
  • Multi-Agency Response Controls Dual Fires in Spokane
  • MoVO Media Marketing Expands CRE Marketing Powerhouse with Addition of Fly Jamerson
  • The Modern Insurance Store Expands Medicare Help Services for Seniors in Cincinnati
  • Hire a Business Plan Writer: What to Expect and Why It's Worth It
  • Ironside HR Named Fastest-Growing Staffing Firm for Second Year
  • Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
  • ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
  • Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
  • $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
  • Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
  • Arcadis welcomes transportation leader Greg Spotts to advance mobility in Seattle and California
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
  • New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
  • SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
  • TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
  • Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
  • Annual Snapshot Estimate of Spokane County's Homeless Population Shows Overall Decrease for Second Year in a Row
_catLbl0 _catLbl1

Popular on Washingtoner

  • purelyIV Blog Named One of the Top 45 IV Therapy Blogs by Feedspot - 136
  • GMO Miner: Creating a simple, efficient and reliable new cloud mining experience - 133
  • Exciting News: Pivotal Health Solutions Acquires Revolutionary Portable Parallel Bars - 129
  • Agreement to Supply US-Based Defense Provider with Thin-Film Solar Tech for Orbital Application; Ascent Solar Technologies, Inc. (N A S D A Q: ASTI) - 109
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care - 103
  • New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient - 101
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives - 101
  • Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
  • DCAS College opens new Representative Office in Malaysian Capital Kuala Lumpur
  • Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI

Similar on Washingtoner

  • Pixel Studio Productions Launches Same-Day Headshots in Houston
  • Spokane River Flows Meet Level 2 Drought Response
  • California Family Launches Billboard to Reach "Pardon Czar" Alice Marie Johnson
  • Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
  • South Tacoma Groundwater Protection District Code Update Public Hearing on August 12
  • WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
  • CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
  • Juvenile suspect in custody after fleeing scene of hit and run collision on Spokane’s South-Hill
  • Tacoma: Small Business Technical Assistance Workshop on July 31
  • Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
Copyright © 2025 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute